Peggy Scherle, Chief Scientific Officer at Prelude Therapeutics Inc (PRLD), sold 12,121 shares at $35.19 ($434K) on 2021-08-26, disclosed to the SEC on 2021-08-30.
Open-market sale of $434k PRLD by Chief Scientific Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $35.19 | 1,700 | $60K | 13.8% |
| 2 | $35.19 | 1,700 | $60K | 13.8% |
| 3 | $35.32 | 2,700 | $95K | 22.0% |
| 4 | $36.23 | 2,707 | $98K | 22.6% |
| 5 | $36.23 | 2,707 | $98K | 22.6% |
| 6 | $37.08 | 607 |
| $23K |
| 5.2% |
| Total | $35.78 avg | 12,121 | $434K | 100% |
| Filing → |
| PRLD | SELL | 2021-05-11 | $808K | — | Filing → |
| PRLD | SELL | 2021-04-15 | $296K | — | Filing → |
| PRLD | SELL | 2021-04-09 | $1.2M | — | Filing → |